drugset / Trial / NCT04938713

Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.

NCT04938713

RandomizedCrossoverTriple-blindTreatment

Summary

Ketamine and Esketamine intravenous perfusions can modulate chronic pain. The purpose of this study is to determine if Ketamine or Esketamine are favorable for outpatients suffering from fibromyalgia.

Timeline

Start
2021-07-01
Primary completion
2022-05-01
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.15 mg/kg Intravenous
Subject Ketamine Small molecule 0.3 mg/kg Intravenous

Indications